← Back to Search

Atorvastatin for Coronavirus (STATCO19 Trial)

Phase 2
Waitlist Available
Led By Lin H Chen, MD
Research Sponsored by Mount Auburn Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Patient aged 18-85 years, admitted with suspected COVID-19 disease based on clinical criteria (typical upper respiratory symptoms, e.g. runny nose, sore throat, dry cough, associated with COVID-19 infection).
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 30 Other Conditions

Summary

This trial looks at whether adding atorvastatin to the usual treatment for COVID-19 can improve clinical outcome in hospitalized patients.

Eligible Conditions
  • Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of patients that progress to severe or critical requiring ICU admission and/or emergency salvage therapy, or death
Secondary study objectives
Overall score of patients in each arm on Day 30 based on WHO Ordinal Scale for Clinical Improvement
Overall score of patients in each arm on Day 7 based on WHO Ordinal Scale for Clinical Improvement
Proportions of patients in each arm who test negative for SARS-CoV-2 on Day 7

Side effects data

From 2014 Phase 3 trial • 58 Patients • NCT02084069
3%
Postoperative bleeding
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment
Control

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 30 Other Conditions
This treatment demonstrated efficacy for 30 other conditions.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TreatmentExperimental Treatment1 Intervention
40 mg
Group II: ControlActive Control1 Intervention
Standard care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atorvastatin
FDA approved

Find a Location

Who is running the clinical trial?

Mount Auburn HospitalLead Sponsor
4 Previous Clinical Trials
26,108 Total Patients Enrolled
Lin H Chen, MDPrincipal InvestigatorMount Auburn Hospital
~56 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top